🔓
Sign in as a Member to unlock the full view of HR.5547. · Full carveout list, all affected companies, party defectors, and 30-day trade predictions.
Become a Member$29.99/mo already a Member? Sign in →
HR.5547 · 118TH CONGRESS

Maintaining Investments in New Innovation Act

Status
Dead
Official Source
Investability
60/100
Stage
COMMITTEE
Related Bills
1
Full Text
1,692 chars
Alive
No

What This Bill Does · Plain English

GovGreed Synthesis · AI extraction
This bill amends the Social Security Act to extend the period of protection from Medicare price negotiation for certain drugs. Specifically, it changes the definition of a 'qualifying single source drug' to give drugs that use 'genetically targeted technologies' an 11-year exemption from price negotiation, instead of the standard 7-year period. This would apply to drugs that modulate gene function, such as some gene therapies and other advanced biologics.

Frequently Asked Questions

Did HR.5547 pass?
HR.5547 did not pass and is no longer active. Final stage: COMMITTEE.
What does HR.5547 do?
This bill amends the Social Security Act to extend the period of protection from Medicare price negotiation for certain drugs. Specifically, it changes the definition of a 'qualifying single source drug' to give drugs that use 'genetically targeted technologies' an 11-year exemption from price negotiation, instead of the standard 7-year period. This would apply to drugs that modulate gene function, such as some gene therapies and other advanced biologics.

Full Bill Text

118 HR 5547 IH: Maintaining Investments in New Innovation Act U.S. House of Representatives 2023-09-18 text/xml EN Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain. I 118th CONGRESS 1st Session H. R. 5547 IN THE HOUSE OF REPRESENTATIVES September 18, 2023 Mr. Nickel (for himself, Mr. Joyce of Pennsylvania , and Mr. Davis of North Carolina ) introduced the following bill; which was referred to the Committee on Energy and Commerce , and in addition to the Committee on Ways and Means , for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned A BILL To amend title XI of the Social Security Act to protect access to genetically targeted technologies. 1. Short title This Act may be cited as the Maintaining Investments in New Innovation Act . 2. Amendment to definition of qualifying single source drug Section 1192(e) of the Social Security Act ( 42 U.S.C. 1320f–1(e) ) is amended— (1) in paragraph (1)(A)(ii), by inserting (or, in the case of an advanced drug product (as defined in paragraph (4)), 11 years) after 7 years ; and (2) by adding at the end the following new paragraph: (4) Advanced drug product defined For purposes of paragraph (1)(A)(ii), the term advanced drug product means a drug that incorporates or utilizes a genetically targeted technology (as defined in section 529A(c)(2) of the Federal Food, Drug, and Cosmetic Act) that may result in the modulation (including suppression, up-regulation, or activation) of the function of a gene or its associated gene product. .
🔒 GovGreed Pro · Trading Intelligence on HR.5547 Get Access — $29.99/mo
Loading intelligence layer…
Bill text sourced from GovInfo.gov · public domain · last updated 2026-11-17. Plain-English summary, score breakdown, and trading-intelligence panels are GovGreed-original analysis derived from STOCK Act filings, SEC Form 4 disclosures, FEC contributions, and Senate LDA lobbying reports — all publicly filed federal records. GovGreed is not affiliated with the U.S. Government. Not financial advice. [live render]